These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 37226302)

  • 1. Genotypic and phenotypic characterization of influenza A viral variants in study participants treated with pimodivir in the phase 2b TOPAZ study.
    Vingerhoets J; Van Dromme I; van Duijnhoven W; Anderson D; De Meyer S; Leopold L
    Antivir Ther; 2023 Jun; 28(3):13596535231174273. PubMed ID: 37226302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial.
    Finberg RW; Lanno R; Anderson D; Fleischhackl R; van Duijnhoven W; Kauffman RS; Kosoglou T; Vingerhoets J; Leopold L
    J Infect Dis; 2019 Mar; 219(7):1026-1034. PubMed ID: 30428049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility of widely diverse influenza a viruses to PB2 polymerase inhibitor pimodivir.
    Patel MC; Chesnokov A; Jones J; Mishin VP; De La Cruz JA; Nguyen HT; Zanders N; Wentworth DE; Davis TC; Gubareva LV
    Antiviral Res; 2021 Apr; 188():105035. PubMed ID: 33581212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase 2 Study of Pimodivir (JNJ-63623872) in Combination With Oseltamivir in Elderly and Nonelderly Adults Hospitalized With Influenza A Infection: OPAL Study.
    O'Neil B; Ison MG; Hallouin-Bernard MC; Nilsson AC; Torres A; Wilburn JM; van Duijnhoven W; Van Dromme I; Anderson D; Deleu S; Kosoglou T; Vingerhoets J; Rossenu S; Leopold L
    J Infect Dis; 2022 Aug; 226(1):109-118. PubMed ID: 32604406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single- and multiple-dose pharmacokinetics and safety of pimodivir, a novel, non-nucleoside polymerase basic protein 2 subunit inhibitor of the influenza A virus polymerase complex, and interaction with oseltamivir: a Phase 1 open-label study in healthy volunteers.
    Deleu S; Kakuda TN; Spittaels K; Vercauteren JJ; Hillewaert V; Lwin A; Leopold L; Hoetelmans RMW
    Br J Clin Pharmacol; 2018 Nov; 84(11):2663-2672. PubMed ID: 30098042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a Phase IIa, randomized, double-blind, placebo-controlled study.
    Trevejo JM; Asmal M; Vingerhoets J; Polo R; Robertson S; Jiang Y; Kieffer TL; Leopold L
    Antivir Ther; 2018; 23(4):335-344. PubMed ID: 29244026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive Profiling of Mutations to Influenza Virus PB2 That Confer Resistance to the Cap-Binding Inhibitor Pimodivir.
    Soh YQS; Malone KD; Eguia RT; Bloom JD
    Viruses; 2021 Jun; 13(7):. PubMed ID: 34206520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural and Thermodynamic Analysis of the Resistance Development to Pimodivir (VX-787), the Clinical Inhibitor of Cap Binding to PB2 Subunit of Influenza A Polymerase.
    Gregor J; Radilová K; Brynda J; Fanfrlík J; Konvalinka J; Kožíšek M
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33673017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents.
    Hayden FG; Sugaya N; Hirotsu N; Lee N; de Jong MD; Hurt AC; Ishida T; Sekino H; Yamada K; Portsmouth S; Kawaguchi K; Shishido T; Arai M; Tsuchiya K; Uehara T; Watanabe A;
    N Engl J Med; 2018 Sep; 379(10):913-923. PubMed ID: 30184455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral resistance due to deletion in the neuraminidase gene and defective interfering-like viral polymerase basic 2 RNA of influenza A virus subtype H3N2.
    Trebbien R; Christiansen CB; Fischer TK
    J Clin Virol; 2018 May; 102():1-6. PubMed ID: 29448067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial.
    Ison MG; Portsmouth S; Yoshida Y; Shishido T; Mitchener M; Tsuchiya K; Uehara T; Hayden FG
    Lancet Infect Dis; 2020 Oct; 20(10):1204-1214. PubMed ID: 32526195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial.
    Beigel JH; Bao Y; Beeler J; Manosuthi W; Slandzicki A; Dar SM; Panuto J; Beasley RL; Perez-Patrigeon S; Suwanpimolkul G; Losso MH; McClure N; Bozzolo DR; Myers C; Holley HP; Hoopes J; Lane HC; Hughes MD; Davey RT;
    Lancet Infect Dis; 2017 Dec; 17(12):1255-1265. PubMed ID: 28958678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.
    Fry AM; Goswami D; Nahar K; Sharmin AT; Rahman M; Gubareva L; Azim T; Bresee J; Luby SP; Brooks WA
    Lancet Infect Dis; 2014 Feb; 14(2):109-18. PubMed ID: 24268590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial.
    Duval X; van der Werf S; Blanchon T; Mosnier A; Bouscambert-Duchamp M; Tibi A; Enouf V; Charlois-Ou C; Vincent C; Andreoletti L; Tubach F; Lina B; Mentré F; Leport C;
    PLoS Med; 2010 Nov; 7(11):e1000362. PubMed ID: 21072246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuraminidase inhibitors for preventing and treating influenza in adults and children.
    Jefferson T; Jones MA; Doshi P; Del Mar CB; Hama R; Thompson MJ; Spencer EA; Onakpoya I; Mahtani KR; Nunan D; Howick J; Heneghan CJ
    Cochrane Database Syst Rev; 2014 Apr; 2014(4):CD008965. PubMed ID: 24718923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children.
    Stephenson I; Democratis J; Lackenby A; McNally T; Smith J; Pareek M; Ellis J; Bermingham A; Nicholson K; Zambon M
    Clin Infect Dis; 2009 Feb; 48(4):389-96. PubMed ID: 19133796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes and Susceptibility to Neuraminidase Inhibitors in Individuals Infected With Different Influenza B Lineages: The Influenza Resistance Information Study.
    van der Vries E; Ip DK; Cowling BJ; Zhang JD; Tong X; Wojtowicz K; Schutten M; Boucher CA
    J Infect Dis; 2016 Jan; 213(2):183-90. PubMed ID: 26160744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment.
    Hayden FG; Treanor JJ; Fritz RS; Lobo M; Betts RF; Miller M; Kinnersley N; Mills RG; Ward P; Straus SE
    JAMA; 1999 Oct; 282(13):1240-6. PubMed ID: 10517426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative analysis of influenza A (H3N2) E119V and R292K variants in clinical specimens by real-time reverse transcription polymerase chain reaction.
    Sato M; Honzumi K; Sato T; Hashimoto K; Watanabe M; Miyazaki K; Kawasaki Y; Hosoya M
    J Clin Virol; 2015 Jul; 68():97-103. PubMed ID: 26071346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of MEDI8852, an Anti-Influenza A Monoclonal Antibody, in Treating Acute Uncomplicated Influenza.
    Ali SO; Takas T; Nyborg A; Shoemaker K; Kallewaard NL; Chiong R; Dubovsky F; Mallory RM
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30150460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.